BioFINDER-Brown: Examination of Alzheimer's Disease Biomarkers
NCT ID: NCT05457998
Last Updated: 2024-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
200 participants
OBSERVATIONAL
2023-06-14
2028-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Main study population: Cognitively unimpaired individuals (50-80 y)
Participants will be enrolled based on a predetermined ratio of Alzheimer's Disease plasma and PET biomarker risk levels (e.g., as P-tau217 and amyloid PET).
FOLLOW-UP FOR 4 YEARS: Cognitive testing, blood draws and retinal imaging will be conducted at baseline and 12 months. Cognitive testing and blood draws will be conducted at 24 months and 36 months.
MRI and amyloid PET scans will be performed at screening/baseline and 24 months. An additional amyloid PET scan will be performed at 48 months.
Flutemetamol F18 Injection
PET imaging of Abeta amyloid
Sub-group 1: Optional Tau PET imaging sub-study
An optional tau PET imaging sub-study will be conducted in 70 subjects from the main study population who elect to participate.
If enrolled in the optional tau PET imaging sub-study, participants will have three tau PET scans with \[18F\]RO-948: at baseline, 24 months, and 48 months.
[18F]-RO6958948 Injection
PET imaging of Tau aggregates
Sub-group 2: Optional Tau PET tracer comparison sub-study
An optional tau PET tracer comparison sub-study will be conducted in 30 subjects from the main study population who elect to participate.
Tau PET scans with 2 tracers (\[18F\]RO-948 and \[18F\]MK-6240) will be performed at baseline and 24 months. An additional Tau PET scan with \[18F\]RO-948 will be performed at 48 months.
[18F]-RO6958948 Injection
PET imaging of Tau aggregates
[18F]-MK-6240 Injection
PET imaging of Tau aggregates
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Flutemetamol F18 Injection
PET imaging of Abeta amyloid
[18F]-RO6958948 Injection
PET imaging of Tau aggregates
[18F]-MK-6240 Injection
PET imaging of Tau aggregates
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Score of 16 or above on the MoCA telephone
* Score of 27 or greater on the MMSE for individuals aged 50 to 64 years old or a score of 26 or greater for individuals aged 65 to 80 years old
* Participants in the 50-60 age range will additionally need to meet at least one of the following: (1) First degree family history of dementia with onset before age 75; (2) APOE e4 allele carrier; or (3) Prior elevated result on amyloid PET or amyloid CSF testing
* Conversationally fluent in English to the extent that an interpreter is not necessary for comprehension of the study information, procedures, and cognitive tests.
* If participants elect to participate in the optional disclosure procedure, they will be required to have an appropriate study partner who agrees to participate in the study and who is intellectually, visually, and auditory capable, and conversationally fluent in English to the extent that an interpreter is not necessary.
* Adequate visual and auditory acuity to allow neuropsychological testing.
* Participants must be willing and able to provide written informed consent.
Exclusion Criteria
* History of significant brain injury or other known neurologic disease or insult, resulting in lasting cognitive sequelae that would confound the assessment and staging of potential neurodegenerative disease (e.g., Huntington's disease, Parkinson's disease, Parkinsonism due to multiple system atrophy (MSA), progressive supranuclear palsy (PSP), Shy Drager Syndrome (SDS) or other neuro-degenerative dementias, encephalitis or other brain infection, epilepsy or stroke with lasting impairment to cognitive function).
* Current serious or unstable systemic illness or organ failure that, in the PI's judgement, would make it difficult to participate in the study (e.g., such as terminal cancer, cardiovascular, hepatic, renal, gastroenterological, respiratory, endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease or other conditions ). History of cancer is acceptable with at least one year in remission with a good prognosis.
* Individuals with clinically significant depression, bipolar disorder, anxiety, or suicidal ideations within the past year as defined by the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM).
* A history of schizophrenia as defined by the most current version of the DSM.
* History within the past year of chronic alcohol or drug abuse/dependence as defined by the most current version of the DSM.
* Marijuana use is acceptable, but frequent users will be asked to abstain from use within 24 hours of any assessments.
* Refusing or unable to complete any study procedures.
* Currently enrolled in another study which involves clinical drug trial or other medical intervention.
50 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Warren Alpert Foundation
UNKNOWN
Brown University
OTHER
University of Rhode Island
OTHER
Hoffmann-La Roche
INDUSTRY
Eli Lilly and Company
INDUSTRY
GE Healthcare
INDUSTRY
Butler Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Edward Huey
Director, Memory and Aging Program, Butler Hospital; Martin M. Zucker Professor of Psychiatry and Human Behavior, Associate Director for Clinical Research, Brown Center for Alzheimer's Disease Research Alpert Medical School of Brown University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Edward Huey, MD
Role: PRINCIPAL_INVESTIGATOR
Butler Hospital Memory and Aging Program
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Butler Hospital Memory and Aging Program
Providence, Rhode Island, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1745146
Identifier Type: -
Identifier Source: org_study_id